Mark T Iwicki Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Mark T Iwicki.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Mark T Iwicki. Mark T Iwicki is EVP & Chief Commercial Officer in Sunovion Pharmaceuticals Inc. ($SEPR) and Chief Executive Officer in Kala Pharmaceuticals, Inc. ($KALA) and Director in Pulmatrix, Inc. ($PULM) and Director in Aimmune Therapeutics, Inc. ($AIMT) and Director in Akero Therapeutics, Inc. ($AKRO).
Latest Insider Trading Transactions of Mark T Iwicki
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, AIMT, AKRO, KALA, PULM, SEPR
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 01 2021 | PULM | Pulmatrix, Inc. | Iwicki Mark T | Director | Option Exercise | A | 1.47 | 15,000 | 22,050 | 15,000 | |
Feb 01 2021 | PULM | Pulmatrix, Inc. | Iwicki Mark T | Director | Option Exercise | A | 1.47 | 15,000 | 22,050 | 15,000 | |
Oct 14 2020 | AIMT | Aimmune Therapeuti ... | Iwicki Mark T | Director | Option Exercise | D | 17.11 | 15,398 | 263,460 | 0 | |
Oct 14 2020 | AIMT | Aimmune Therapeuti ... | Iwicki Mark T | Director | Option Exercise | D | 19.90 | 11,432 | 227,497 | 0 | |
Oct 14 2020 | AIMT | Aimmune Therapeuti ... | Iwicki Mark T | Director | Option Exercise | D | 32.79 | 7,500 | 245,925 | 0 | |
Oct 14 2020 | AIMT | Aimmune Therapeuti ... | Iwicki Mark T | Director | Option Exercise | D | 18.26 | 17,500 | 319,550 | 0 | |
Oct 14 2020 | AIMT | Aimmune Therapeuti ... | Iwicki Mark T | Director | Option Exercise | D | 15.40 | 19,755 | 304,227 | 0 | |
Oct 14 2020 | AIMT | Aimmune Therapeuti ... | Iwicki Mark T | Director | Option Exercise | D | 6.29 | 87,368 | 549,545 | 0 | |
Oct 14 2020 | AIMT | Aimmune Therapeuti ... | Iwicki Mark T | Director | Option Exercise | D | 3.02 | 52,421 | 158,311 | 0 | |
Oct 14 2020 | AIMT | Aimmune Therapeuti ... | Iwicki Mark T | Director | Sell | D | 34.50 | 7,840 | 270,480 | 0 | 7.8 K to 0 (-100.00 %) |
Oct 14 2020 | AIMT | Aimmune Therapeuti ... | Iwicki Mark T | Director | Sell | U | 34.50 | 39,567 | 1,365,062 | 0 | 39.6 K to 0 (-100.00 %) |
Jun 29 2020 | KALA | Kala Pharmaceutica ... | Iwicki Mark T | Chief Executive Off ... | Grant | A | 0.00 | 49,560 | 0 | 49,560 | 0 to 49.6 K |
Jun 02 2020 | AKRO | Akero Therapeutics ... | Iwicki Mark T | Director | Option Exercise | A | 25.20 | 13,000 | 327,600 | 13,000 | |
May 29 2020 | AIMT | Aimmune Therapeuti ... | Iwicki Mark T | Director | Option Exercise | A | 17.11 | 15,398 | 263,460 | 15,398 | |
May 29 2020 | AIMT | Aimmune Therapeuti ... | Iwicki Mark T | Director | Grant | A | 0.00 | 7,840 | 0 | 47,407 | 39.6 K to 47.4 K (+19.81 %) |
Apr 06 2020 | PULM | Pulmatrix, Inc. | Iwicki Mark T | Director | Option Exercise | A | 1.28 | 10,000 | 12,800 | 10,000 | |
Jan 13 2020 | PULM | Pulmatrix, Inc. | Iwicki Mark T | Director | Option Exercise | A | 1.54 | 15,000 | 23,100 | 15,000 | |
Jan 03 2020 | KALA | Kala Pharmaceutica ... | Iwicki Mark T | Chief Executive Off ... | Option Exercise | A | 3.84 | 365,000 | 1,401,600 | 365,000 | |
May 28 2019 | AIMT | Aimmune Therapeuti ... | Iwicki Mark T | Director | Option Exercise | A | 19.90 | 11,432 | 227,497 | 11,432 | |
May 28 2019 | AIMT | Aimmune Therapeuti ... | Iwicki Mark T | Director | Grant | A | 0.00 | 6,442 | 0 | 39,567 | 33.1 K to 39.6 K (+19.45 %) |
May 20 2019 | PULM | Pulmatrix, Inc. | Iwicki Mark T | Director | Option Exercise | A | 1.06 | 15,000 | 15,900 | 15,000 | |
Jan 04 2019 | KALA | Kala Pharmaceutica ... | Iwicki Mark T | Chief Executive Off ... | Option Exercise | A | 5.19 | 460,000 | 2,387,400 | 460,000 | |
Jun 06 2018 | PULM | Pulmatrix, Inc. | Iwicki Mark T | Director | Option Exercise | A | 0.47 | 155,000 | 72,540 | 155,000 | |
May 24 2018 | AIMT | Aimmune Therapeuti ... | Iwicki Mark T | Director | Option Exercise | A | 32.79 | 7,500 | 245,925 | 7,500 | |
May 24 2018 | AIMT | Aimmune Therapeuti ... | Iwicki Mark T | Director | Grant | A | 0.00 | 3,750 | 0 | 33,125 | 29.4 K to 33.1 K (+12.77 %) |
Apr 05 2018 | PULM | Pulmatrix, Inc. | Iwicki Mark T | Director | Option Exercise | P | 0.75 | 307,000 | 230,250 | 307,000 | |
Apr 05 2018 | PULM | Pulmatrix, Inc. | Iwicki Mark T | Director | Option Exercise | P | 0.65 | 307,000 | 199,550 | 307,000 | |
Apr 05 2018 | PULM | Pulmatrix, Inc. | Iwicki Mark T | Director | Buy | P | 0.00 | 307,000 | 0 | 307,000 | 0 to 307 K |
Feb 26 2018 | AIMT | Aimmune Therapeuti ... | Iwicki Mark T | Director | Buy | P | 32.00 | 9,375 | 300,000 | 29,375 | 20 K to 29.4 K (+46.88 %) |
Feb 09 2018 | KALA | Kala Pharmaceutica ... | Iwicki Mark T | Chief Executive Off ... | Option Exercise | A | 12.86 | 230,000 | 2,957,800 | 230,000 | |
Jul 21 2017 | KALA | Kala Pharmaceutica ... | Iwicki Mark T | Chief Executive Off ... | Option Exercise | A | 15.00 | 78,632 | 1,179,480 | 78,632 | |
May 30 2017 | AIMT | Aimmune Therapeuti ... | Iwicki Mark T | Director | Option Exercise | A | 18.26 | 17,500 | 319,550 | 17,500 | |
Mar 22 2017 | PULM | Pulmatrix, Inc. | Iwicki Mark T | Director | Option Exercise | A | 2.78 | 4,400 | 12,232 | 4,400 | |
May 27 2016 | AIMT | Aimmune Therapeuti ... | Iwicki Mark T | Director | Option Exercise | A | 15.40 | 19,755 | 304,227 | 19,755 | |
Dec 09 2015 | PULM | Pulmatrix, Inc. | Iwicki Mark T | Director | Option Exercise | A | 4.75 | 73,481 | 349,035 | 73,481 | |
Aug 11 2015 | AIMT | Aimmune Therapeuti ... | Iwicki Mark T | Director | Buy | P | 16.00 | 20,000 | 320,000 | 20,000 | 0 to 20 K |
Oct 22 2009 | SEPR | Sunovion Pharmaceu ... | Iwicki Mark T | EVP & Chief Commerc ... | Option Exercise | D | 14.40 | 57,500 | 828,000 | 0 | |
Oct 22 2009 | SEPR | Sunovion Pharmaceu ... | Iwicki Mark T | EVP & Chief Commerc ... | Option Exercise | D | 21.26 | 42,165 | 896,428 | 0 | |
Oct 22 2009 | SEPR | Sunovion Pharmaceu ... | Iwicki Mark T | EVP & Chief Commerc ... | Sell | D | 23.00 | 122,334 | 2,813,682 | 0 | 122.3 K to 0 (-100.00 %) |
Oct 19 2009 | SEPR | Sunovion Pharmaceu ... | Iwicki Mark T | EVP & Chief Commerc ... | Sell | U | 23.00 | 27,666 | 636,318 | 122,334 | 150 K to 122.3 K (-18.44 %) |
May 14 2009 | SEPR | Sunovion Pharmaceu ... | Iwicki Mark T | EVP & Chief Commerc ... | Option Exercise | A | 14.40 | 57,500 | 828,000 | 57,500 | |
May 14 2009 | SEPR | Sunovion Pharmaceu ... | Iwicki Mark T | EVP & Chief Commerc ... | Grant | A | 14.40 | 35,000 | 504,000 | 150,000 | 115 K to 150 K (+30.43 %) |
May 22 2008 | SEPR | Sunovion Pharmaceu ... | Iwicki Mark T | EVP & Chief Commerc ... | Option Exercise | A | 21.26 | 42,165 | 896,428 | 42,165 | |
May 22 2008 | SEPR | Sunovion Pharmaceu ... | Iwicki Mark T | EVP & Chief Commerc ... | Grant | A | 21.26 | 35,000 | 744,100 | 115,000 | 80 K to 115 K (+43.75 %) |
Oct 22 2007 | SEPR | Sunovion Pharmaceu ... | Iwicki Mark T | EVP & Chief Commerc ... | Option Exercise | A | 24.89 | 150,000 | 3,733,500 | 150,000 | |
Oct 22 2007 | SEPR | Sunovion Pharmaceu ... | Iwicki Mark T | EVP & Chief Commerc ... | Grant | A | 24.89 | 80,000 | 1,991,200 | 80,000 | 0 to 80 K |
Page: 1